Small Biotechs Are Pulling Public Offerings, IPOs Amid ‘Current Market Conditions’
RNA biotech TransCode Therapeutics Inc (NASDAQ:RNAZ) withdrew its S-1 filing with the SEC that it made in late November. TransCode said…
Free Ketamine Therapy? Laid Off Tech Workers Can Request Month Of ‘Freedom’ Program
A considerable number of employees have been fired from their jobs at big tech firms.
ADMA Biologics Announces Pricing Of Public Offering For $6M Of Common Stock
ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived
X4 Pharmaceuticals Prices $65M Public Offering
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced today the pricing of its
Versus Systems Prices 2.1M Unit Offering For Gross Proceeds Of ~$2.1M
LOS ANGELES, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Versus Systems Inc. ("Versus" or the "Company") (NASDAQ:VS) today announced the pricing of its public offering of 2,100,000 units for gross proceeds of
Syndax Late Tuesday Announced it Priced ~6.8M Public Share Offering of Common Stock @$22/Share
Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (NASDAQ: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced the pricing of an underwritten public offering of 6,818,182 shares of its common stock.
Reported Late Tuesday, iBio Announces Pricing Of $3.5M Underwritten Public Offering Of 3,365,385 Shares Of Common Stock At A Price Of $1.04/Share
iBio, Inc. (NYSEA: IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody immunotherapies, today announced the pricing of its previously announced underwritten public offering
Reported Late Tuesday, X4 Pharmaceuticals Announces Proposed Public Offering; No Size Disclosed
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR), a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced today that it has commenced an